Omicron sublineage BQ.1.1 resistance to monoclonal antibodies

Vaccination represents the key strategy to control the COVID-19 pandemic through induction of neutralising antibody responses and T cell-associated immunity that substantially decrease the risk of developing severe disease.1,2 However, individuals who are immunocompromised (eg, because of comorbidit...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2023-01, Vol.23 (1), p.22-23
Main Authors: Arora, Prerna, Kempf, Amy, Nehlmeier, Inga, Schulz, Sebastian R, Jäck, Hans-Martin, Pöhlmann, Stefan, Hoffmann, Markus
Format: Article
Language:English
Subjects:
Adaptive immunity
Antibodies, Monoclonal - therapeutic use
Antibodies, Neutralizing
Antibodies, Viral
Comorbidity
Coronaviruses
Correspondence
COVID-19
Disease transmission
Epitopes
Humans
Immune response
Immune system
Infectious diseases
Lymphocytes
Lymphocytes T
Monoclonal antibodies
Mutation
Pandemics
Prophylaxis
Proteins
Risk
Severe acute respiratory syndrome coronavirus 2
Vaccination
Viral diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccination represents the key strategy to control the COVID-19 pandemic through induction of neutralising antibody responses and T cell-associated immunity that substantially decrease the risk of developing severe disease.1,2 However, individuals who are immunocompromised (eg, because of comorbidities, high age, or immunosuppressive treatment) might not mount a full adaptive immune response and thus remain susceptible. For individuals at high risk, individual monoclonal antibodies (mAbs) or cocktails of mAbs are administered as prophylaxis or therapy.3,4 All mAbs currently approved by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA) target the spike (S) protein (appendix pp 1–2).5 During the course of the COVID-19 pandemic, several SARS-CoV-2 lineages evolved mutations that confer partial or full resistance against some mAbs.6–9 Consequently, only few mAbs remain suitable for treatment of individuals at high risk, and only bebtelovimab shows high efficacy against multiple omicron sublineages.8 However, novel omicron sublineages have been detected, harbouring additional S protein mutations within the epitopes of bebtelovimab and other mAbs (figure A; appendix p 11). [...]none of the tested mAbs or mAb cocktails caused appreciable neutralisation of BQ.1.1pp (figure B–C; appendix p 12).
ISSN:1473-3099
1474-4457
1474-4457
DOI:10.1016/S1473-3099(22)00733-2